239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval
Executive Summary
Withdrawal announcement marks shortest interval ever from accelerated approval to market removal after OCEAN confirmatory trial showed an adverse overall survival trend and US FDA said a hypothesis-generating subgroup analysis would need to be borne out in another study.
You may also be interested in...
Accelerated Approval: US FDA’s Hammer Falls On Oncopeptides’ Pepaxto
Rejecting company’s appeal, CBER Director Peter Marks says the multiple myeloma drug should be withdrawn because its confirmatory trial failed to verify clinical benefit and evidence demonstrates the drug is not safe and effective for its current indication.
Pepaxto Withdrawal Dispute: Oncopeptides Details Plans For New Studies
An observational single-arm study and a dose-optimization study are planned if the FDA does not withdraw accelerated approval of the multiple myeloma drug, Oncopeptides says. If an additional confirmatory trial is needed, company suggests two different approaches, one of which is almost a repeat of the OCEAN study, the results of which remain in dispute.
Accelerated Approval: Oncopeptides' Pepaxto Will Test New Expedited Withdrawal Process
Company’s appeal of the US FDA’s formal request to voluntarily withdraw accelerated approval of the multiple myeloma agent is expected to follow the streamlined procedures created in last year’s omnibus legislation, which would preclude a second advisory committee review of melflufen’s fate.